Previous 10 | Next 10 |
-- Preclinical findings show that ONCR-177’s systemic antitumor immunity is driven by its five complementary immunomodulatory transgene payloads and retention of γ 34.5 -- -- Complete and durable tumor regression and protective antitumor memory observed in mu...
Gainers: GeoVax Labs (GOVX) +83%, Zomedica (ZOM) +82%, TransEnterix (TRXC) +49%, Mesoblast (MESO) +40%, Aileron Therapeutics (ALRN) +29%.Losers: Editas Medicine (EDIT) -16%, Medigus (MDGS) -15%, Jaguar Health (JAGX) -11%, Invita...
Oncorus ([[ONCR]] +0.6%) has signed a 15-year lease to build a state-of-the-art, 88,000 sq ft viral immunotherapy clinical manufacturing facility in Andover, Mass.The company anticipates the first phase of the facility’s buildout will be completed in late 2021, including proc...
-- 88,000 square foot state-of-the-art facility will support Oncorus’ advancing, multi-product pipeline of intratumorally and intravenously administered viral immunotherapies – -- Initial phase of site buildout anticipated to be completed in fourth quarter 2021 -...
CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Scott Canute, M.B.A. to its Board of Di...
CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced the appointment of Steve Harbin as Chief Operating Officer...
CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced today that Theodore (Ted) A. Asbhurn, M.D., Ph.D., President and Chief Executive Officer, will ...
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced today that Theodore (Ted) A. Asbhurn, M.D., Ph.D., President and Chief Executive Officer, will ...
Oncorus (ONCR): Q3 GAAP EPS of -$21.73.Cash and cash equivalents of $54M.Press Release For further details see: Oncorus reports Q3 results
-- Received $98.4 million in aggregate gross proceeds in October from initial public offering -- -- Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of solid tumors -- -- A nnounced c linical trial collab...
News, Short Squeeze, Breakout and More Instantly...
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...